10:01 AM EST - Microbix Biosystems Inc. : Announced that it is presenting results of Quality Assessment Products for supporting the quality control of histology and PCR-based tests driven by tissue-samples of Head and Neck cancer caused by human papilloma virus. Its results presentation will be made at EUROGIN 2024, an international collaborative conference and exhibition focused upon innovations in HPV research and global cancer solutions taking place in Stockholm, Sweden from March 13 to 16. Microbix Biosystems Inc.
shares T.MBX are trading unchanged at $0.39.
